J.B. Williams making Cepacol ColdCare zinc lozenges cold claim despite "courtesy letter".
This article was originally published in The Tan Sheet
Executive Summary
J.B. WILLIAMS CEPACOL COLDCARE ZINC LOZENGES COLD CLAIM will remain on packaging, the firm said in response to an Oct. 9 "courtesy letter" from FDA. On Sept. 25, the firm notified FDA it would be marketing the dietary supplement Cepacol ColdCare Zinc Acetate Lozenges with the structure/function claim, "Taken as a dietary supplement, Cepacol ColdCare helps promote general well-being during the cold season." FDA states the claim and the product name, "taken together, suggest that it is intended to treat, mitigate, or prevent a disease, namely the common cold," and the product is thus an unapproved new drug.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: